Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
March 06 2024 - 1:00AM
Business Wire
- IPH45 abstract selected for oral presentation at AACR Annual
Meeting 2024
- Preclinical data support further development of IPH45,
a differentiated topoisomerase I inhibitor ADC targeting
Nectin-4, which is progressing towards the clinic
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) today announced that an
abstract regarding its preclinical asset IPH45, a novel and
differentiated topoisomerase I inhibitor Antibody Drug Conjugate
(ADC) targeting Nectin-4, has been selected for oral presentation
at the American Association for Cancer Research (AACR) Annual
Meeting 2024, taking place April 5-10 in San Diego, California.
"We are excited to present our findings on IPH45 at this year's
AACR. IPH45 is a cutting-edge ADC that delivers a topoisomerase I
inhibitor to tumors expressing Nectin-4. Our studies demonstrate
that IPH45 effectively inhibits tumor growth both in vitro and in
vivo, and it exhibits a favorable safety profile in preclinical
studies," stated Prof. Eric Vivier, DVM, PhD, Chief Scientific
Officer at Innate Pharma. "These promising results underscore
the potential of IPH45 and reflect our dedication to pioneering the
next wave of cancer treatments through advanced antibody
engineering. Based on these encouraging data, we are eagerly
advancing IPH45 towards clinical trials."
Details of the presentation
- Preclinical characterization of IPH45, a novel topoisomerase I
inhibitor ADC targeting Nectin‑4 for the treatment of Nectin-4
expressing tumors Abstract Presentation Number: 6582
Session Type: Minisymposium Session Category:
Experimental and Molecular Therapeutics Session Title: Drug
Discovery 2: New Therapies Session Date/Time: Tuesday Apr 9,
2024 2:30 PM - 4:30 PM
More information can be found on the AACR website.
About IPH45
Nectin-4 is a cell membrane adhesion protein overexpressed in
several solid tumors, including urothelial, breast, lung, ovarian,
and pancreatic cancers, with limited expression in normal tissues.
IPH45 is a novel topoisomerase I inhibitor Antibody Drug Conjugate
(ADC) targeting Nectin-4. In non-clinical models, IPH45 is well
tolerated and shows anti-tumor efficacy in vitro and in vivo. IPH45
is progressing towards First in Human Studies.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through therapeutic antibodies and its ANKET®
(Antibody-based NK cell Engager
Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab,
developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, monalizumab developed with AstraZeneca
in non-small cell lung cancer, as well as ANKET® multi-specific NK
cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com and
follow us on Twitter and LinkedIn.
Information about Innate Pharma shares
ISIN code
FR0010331421
Ticker code
Euronext: IPH Nasdaq: IPHA
LEI
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts and the Company’s continued
ability to raise capital to fund its development. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2022,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240305421795/en/
For additional information, please contact: Investors
Innate Pharma Henry Wheeler Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Innate Pharma (NASDAQ:IPHA)
Historical Stock Chart
From May 2024 to Jun 2024
Innate Pharma (NASDAQ:IPHA)
Historical Stock Chart
From Jun 2023 to Jun 2024